Skip to main content

Month: August 2022

Proactive news headlines including Aldoro Resources, Hygrovest Ltd, Australian Gold and Copper and Tamboran Resources

Sydney, Aug. 12, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Aldoro Resources Ltd (ASX:ARN) has confirmed the presence of lithium and rubidium mineralisation from recent test studies performed on Niobe and Wyemandoo samples by the University of Western Australia (UWA). Click here Hygrovest Ltd (ASX:HGV)’s net asset value (NAV) increased by 6% during July 2022, primarily due to the revaluation of its investment in Weed Me and Southern Cannabis Holdings. Click here Australian Gold and Copper Ltd (ASX:AGC) has strengthened its board with the appointment of experienced mining industry executive Dr Adam McKinnon as a non-executive director. Click here Tamboran Resources Ltd (ASX:TBN) is poised to drill up to seven natural...

Continue reading

AKVA group ASA: Q2 2022 financial reporting

Record high revenues with cost related headwinds AKVA group delivered record high revenue for Q2 of MNOK 907 (832), an increase of 9% compared to Q2 2021. EBITDA decreased from MNOK 79 in Q2 2021 to MNOK 3 in Q2 2022. The Net Profit decreased from MNOK 16 last year to MNOK -41 in Q2 2022. The order intake in the quarter was MNOK 827 with a backlog of BNOK 1.8 at the end of June 2022. Profitability negatively impacted by estimated MNOK 102 from high inflation rates and one-time cost provisions. During Q4 2021 AKVA group experienced somewhat challenging profit margins due to cost inflations and global supply chain restrictions. This has been further intensified in H1 2022 due to the war between Ukraine and Russia. Examples include increased freight rates, high energy prices and increased price level on raw materials and key components...

Continue reading

Lerøy Seafood Group ASA: Invitation to Capital Markets Day for 2022

Lerøy Seafood Group ASA have the pleasure of inviting to its inaugural capital markets day on September 22nd-23rd, 2022 in Hitra, Norway. On September 22nd, management will present strategic priorities focusing on the group’s fully integrated value chain as well the farming segment. On September 23rd, a tour through Lerøy’s operations in Mid-Norway (Lerøy Midt) will be offered to participants, including visits to one of the world’s most automated processing sites for salmon and one of the world’s larger post-smolt facilities, based on RAS-technology. The presentations will commence on September 22nd at 12:00 am. The tour on September 23rd will end within 13:00 pm. Common bus transport from Trondheim Airport to Hitra and back will be offered to participants. The bus will depart from the airport on September 22nd at 08:30 am...

Continue reading

NNIT A/S: Financial report for the first six months of 2022

NNIT announced the transformative divestment of the Group’s infrastructure business, initiated the carve-out process and continued the efforts to consolidate global delivery capabilities in Q2 2022, which was marked by slower-than-expected sales performance. The temporary suspension of NNIT’s full-year outlook is maintained. Financial highlights for the second quarter 2022Group revenue increased 1.8% (-6.8% organic) to DKK 723 million driven by acquisitions and moderate growth in Life Sciences Solutions outweighed by slow sales overall and lower revenue from the Global Infrastructure Agreement with Novo Nordisk. The operating profit before special items decreased to DKK -11 million from DKK 36 million impacted by the renegotiated Novo Nordisk contract and temporarily lower capacity utilization. The operating profit margin declined to...

Continue reading

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2022 (UNAUDITED)

Company announcement, Helsinki, August 12, 2022 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2022 (UNAUDITED) THE BEST HALF-YEAR IN NEXSTIM’S HISTORY IN TERMS OF NET SALES AND OPERATING RESULT The figures in parentheses refer to the previous year’s comparative period, unless otherwise stated. January–June 2022 in briefThe company’s net sales increased by 129.6%, to EUR 6.8 million (3.0). Net sales growth adjusted for currency exchange rates was 110.3%. Equipment sales were EUR 1.8 million (1.6), with an increase of 11.1%. Continuous net sales accounted for EUR 1.5 million (1.4), with an increase of 9.0%. The licensing business accounted for EUR 3.5 million (0.0). The net sales of the diagnostics business (NBS) increased by 19.3% during the first half of the year, to EUR 2.1 million (1.8). The net sales of the therapy...

Continue reading

INVL Baltic Real Estate’s design proposals approved for reconstruction of complex in Vilnius Old Town

INVL Baltic Real Estate (hereinafter – the Company) hereby gives notification that the Vilnius City municipality has approved design proposals for the reconstruction of a complex that the Company owns in the city’s Old Town at the address Vilniaus Street 33. Reconstruction of the complex is intended to create an administrative building with four floors and an attic for high-end offices. Its ground floor will contain restaurants and commercial premises. Additional information: The Vilnius City municipality has approved design proposals for the reconstruction of a complex that the real estate investment company INVL Baltic Real Estate owns in the city’s Old Town. “Working with the design firm Viltekta and architect Julius Šeibokas, son of the author of the existing complex, we found optimal solutions for reconstructing the buildings at Vilniaus...

Continue reading

Changes in management board of AS Harju Elekter

Supervisory board of AS Harju Elekter elected Mr Priit Treial as the new member of the board and chief financial officer of the company, taking office on 14 November 2022 and his term of office is three years. Priit Treial has been a member of the board and chief financial officer of Elektrilevi OÜ since 2018, and a member of the council of Narva Soojus AS and Imatra Elekter AS since 2021. In 2016-2018, he worked as a financial controller at Eesti Energia AS. In addition, he has long-term work experience as an investment analyst and group business controller from the commercial real estate company BPT Real Estate AS. Priit received his bachelor’s degree in 2006 from the University of Tartu in economics. Priit Treial is the sole shareholder and member of the board of PHT Chemicals OÜ. He does not own Harju Elekter shares. Starting from...

Continue reading

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

Geneva, Switzerland, August 12, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title:                 Addex Therapeutics to Announce Half-Year 2022 Financial Results and Provides Corporate UpdateDate:                August 18, 2022Time:                16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) Joining the Conference Call:Participants are required to register in advance of the conference using the link provided below. Upon registering,...

Continue reading

Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks the first single-dose oral influenza medicine approved in the US for children in this age group. Additionally, the FDA approved Xofluza for...

Continue reading

Unifiedpost shows continued double-digit growth in first semester of 2022

Logo Logo Unifiedpost GroupConsistent growth of revenue and customer base demonstrates momentum for digital business Regulated Information La Hulpe, Belgium – August 12, 2022, 7:00 a.m. CET – Unifiedpost Group’s (Euronext: UPG) (Unifiedpost, the Group or the Company) revenue in the first half year of 2022 increased by 13.6% y/y to €91.7 million. This substantial increase was mainly driven by the double-digit underlying growth in recurring digital revenue (+21.7%), which is at the core of the business of the Company. Unifiedpost expects further double-digit growth due to the accelerated adoption of e-invoicing throughout Europe. HighlightsGroup revenue grew by 13.6% y/y to €91.7 million for H1 2022 Recurring digital processing revenue up by 21.7% y/y in H1 2022 Including project and license business, total digital processing revenue...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.